A Study of LY3437943 in Healthy Participants With a High Body Mass Index
Completed · Phase 1 · NCT05959096
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 85
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3437943 (drug), LY3437943 (drug)
- Dates
- Started 2023-07-18; completion 2024-07-25
- Results posted
- Not yet
The study is conducted in two parts (Part A and B). The main purpose of this study is to look at the amount of the LY3437943 that gets into the blood stream and how long it takes the body to get rid of it when given subcutaneously (SC, under the skin) in the upper arm and thigh compared to the abdomen in healthy participants with high body mass index (BMI) in Part A. In Part B, the participants receive LY3437943 intravenously (IV, through a vein) where the safety and tolerability of LY3437943 are evaluated and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 157 days and 99 days for Part A a…
From ClinicalTrials.gov, last updated 2024-10-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.2M in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $1.2M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.